Analysis of which side effects require stopping taking Mobosetinib (Anvili)

Mobocertinib (trade name: Anweili) is an oral EGFR exon 20 insertion mutation selective inhibitor, mainly used for EGFRExon 20Insertion mutation-positive advanced non-small cell lung cancer (NSCLC). In clinical application, Mobocertinib can effectively inhibit tumor growth, but may also cause varying degrees of adverse reactions. Knowing when medication needs to be discontinued is critical to patient safety and efficacy.

MobocertinibCommon side effects include diarrhea, rash, stomatitis, nausea, fatigue, and abnormal liver function. Mild to moderate side effects can usually be relieved with supportive care or dose adjustment without complete discontinuation of the drug. For example, mild diarrhea can be controlled with oral rehydration and antidiarrheal drugs; mild rashes can be relieved with topical ointments or oral antihistamines.

In the event of serious or intolerable side effects , medication should be discontinued immediately, including:

1.Severe diarrhea or dehydration, leading to electrolyte imbalance or impaired kidney function;

2.Severe liver function damage, such as ALT/AST being significantly elevated to more than 5 times the upper limit of normal, accompanied by jaundice or abnormal coagulation;

3.Severe rash or drug eruption, accompanied by general itching, blisters or mucosal involvement;

4.Other life-threatening adverse events, such as serious cardiac events or acute allergic reactions.

After discontinuing the medication, patients need to closely monitor symptoms and laboratory indicators. After symptoms are relieved or indicators recover, the dosage can be reduced or re-administered according to the doctor's advice .

In order to use the drug safely, patients should have regular follow-up of liver and kidney function, hematological indicators and clinical symptoms during Mobocertinib treatment. The doctor will evaluate whether to continue taking the medication, adjust the dose, or suspend treatment based on the severity of the adverse reaction. At the same time, providing supportive treatment, lifestyle intervention and nutritional management can reduce the incidence of side effects. Mastering these indications for discontinuation can help minimize risks while ensuring efficacy, and improve patients' long-term compliance and quality of life.

Reference materials:https://www.drugs.com/